1-2 of 2
Donald Strickland, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R Patel, MD, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald Strickland, MD, Suzanne Jones, PharmD, Philip Overend, Carrie A. Adelman, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Wolfram Brugger, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4064.
https://doi.org/10.1182/blood-2018-99-118465
Published: 2018
Journal Articles

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

Wolfram Brugger, MDPhD, Susan Ashton, Carrie A. Adelman, Nicolas Floc'h, Paula Taylor, Maureen Hattersley, PhD, Shenghua Wen, Kimberly Maratea, Philip Overend, Steven Fox, Julie Charlton, Simon T Barry, Donald Strickland, MD, Suzanne Jones, PharmD, Howard A. Burris, MD, Carol Greenlees, Alexander MacDonald, J. Elizabeth Pease, PhD, William Donnellan
Journal: Blood
Blood (2017) 130 (Supplement 1): 1368.
https://doi.org/10.1182/blood.V130.Suppl_1.1368.1368
Published: 2017